News

Researchers have developed a highly selective and sensitive test to detect neuropilin-2 (NRP2), the therapeutic protein target of efzofitimod, an experimental treatment for pulmonary sarcoidosis by aTyr Pharma. Using immunohistochemical (IHC) detection methods, the new antibody-based tool — created in collaboration with Michael Muders, at the University Hospital…

The chance of developing sarcoidosis is nearly halved in those with obstructive sleep apnea (OSA), a sleeping disorder wherein breathing slows or stops repeatedly and for short times during sleep, according to a large study involving U.S. veterans. The findings point to OSA as a protective factor for sarcoidosis.

Patients with sarcoidosis of the heart, called cardiac sarcoidosis, with no other organ involved have more advanced symptoms at their first doctor visit than those with prior involvement of organs other than the heart, a study found. With time, they also develop a type of irregular heartbeat called ventricular…

The Foundation for Sarcoidosis Research (FSR) has awarded pulmonologist Nancy Lin, MD, at National Jewish Health, the FSR Sarcoidosis Research Fellowship for 2022–2024. Her project, “Defining MicroRNA Biomarkers in Sarcoidosis,” has been granted $150,000 over two years to improve the management of people with sarcoidosis through the identification of…

Efzofitimod, an experimental treatment for pulmonary sarcoidosis that’s set to begin Phase 3 clinical testing later this year, has been granted fast track designation by the U.S. Food and Drug Administration (FDA). This designation is designed to speed up the development and review of investigational treatments that aim…

People with sarcoidosis in three of the hardest hit English-speaking cities during the initial stages of the COVID-19 pandemic — London, New Orleans, and New York — reported considerable disruptions in healthcare, a survey study has found. Patients also had concerns for their own survival and believed that they were…

Temple Lung Center at Temple Health in Philadelphia has become a founding member of the Foundation for Sarcoidosis Research (FSR) Global Sarcoidosis Clinic Alliance, a group of clinics and hospitals around the world that aims to improve the lives of sarcoidosis patients through care and research advancement. “Sarcoidosis is…

The Foundation for Sarcoidosis Research (FSR) has hosted a virtual session attended by people with pulmonary sarcoidosis and representatives from the U.S. Food and Drug Administration (FDA). FDA Patient Listening Sessions are small, informal, non-public meetings that discuss medical conditions from a patient’s perspective. The sessions seek to…

Nonprofits, scientists, governmental organizations, and the rare disease drug development industry have long cited 7,000 as the average number of rare diseases in the world. But a new analysis shows there are as many as 10,867 rare diseases globally. And that…

After the success of its virtual event last year, the Foundation for Sarcoidosis Research (FSR) is gearing up to once again host an online summit for all those impacted by sarcoidosis. The “Third Annual Global Virtual Patient Summit: Unveiling Possibilities” is set for July 30–31. Billed as the…